In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ed Silverman

Latest From Ed Silverman

US FTC Targets Pharma Patent Abuse: What You Need to Know

The FTC is intensifying its crackdown on pharmaceutical companies' misuse of patent listings as industry seeks clearer guidelines.

Patents Business Strategies

The John Green Effect: Will Industry Be Influenced Again?

Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry. 

Business Strategies Commercial

Pressure Mounts On Pharma To Act On Environmental Targets

There are growing demands from government officials, investors and employees for the pharmaceutical industry to reduce emissions and waste, and – most of all – make environmental sustainability a core part of its business.

Commercial Strategies Business Strategies

Would You Like Chips With That? High-Tech Alternatives Could Replace Animal Testing

The FDA Modernization Act 2.0 should make it easier for companies to gain regulatory authorization using non-traditional testing methods, like organs-on-a-chip. But biopharma will need to make the leap into technology to help build knowledge and data if the drug development world is to move away from animal testing entirely. 

Clinical Trials Digital Health

Uncertainty Clouds Pharma Patent Validity As SCOTUS Ruminates On Amgen Case

The pharma and biotech industry is waiting with bated breath for the decision from the US Supreme Court over a contentious case involving Amgen. The result of the SCOTUS decision could have a huge impact on drugmakers’ profits, commercial strategy, and industry innovation.

Innovation Intellectual Property

Solutions To The AMR ‘Silent Pandemic’ Need More Than Just Lip Service

With new antibiotics a rare commodity, persistently inadequate reimbursement for innovations and worthy but often piecemeal pilots, antimicrobial resistance has quietly risen to become a factor in well over a million deaths annually. Now that COVID-19 is not the all-encompassing threat to health it was until fairly recently, AMR is once again moving towards the center of attention. But properly funded actions and mindset changes are needed.

Infectious Diseases BioPharmaceutical
See All
UsernamePublicRestriction

Register